Bgp Pharma ULC Sustainability Profile
Bgp Pharma ULC, headquartered in Canada, is a prominent player in the pharmaceutical industry, specialising in the development and distribution of innovative healthcare solutions. Founded in [year], the company has established a strong presence across major operational regions, focusing on both prescription and over-the-counter medications. With a commitment to quality and efficacy, Bgp Pharma ULC offers a diverse range of products, including generics and specialty pharmaceuticals. Their unique approach to research and development has led to several key milestones, positioning them as a trusted name in the market. Notably, the company has achieved significant recognition for its contributions to patient care and has built a reputation for excellence in pharmaceutical manufacturing.
DitchCarbon Score
How does Bgp Pharma ULC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bgp Pharma ULC's score of 45 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bgp Pharma ULC, headquartered in Canada, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Viatris Inc., which means that any relevant emissions data or climate commitments may be inherited from its parent organisation. As part of its corporate family relationship with Viatris Inc., Bgp Pharma ULC aligns with the climate initiatives and targets set by Viatris. However, specific reduction targets or achievements for Bgp Pharma ULC itself have not been disclosed. The absence of documented reduction initiatives or climate pledges indicates that the company may still be in the process of establishing its own distinct climate strategy. For context, Viatris Inc. has committed to various sustainability initiatives, including those related to the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which may influence Bgp Pharma ULC's future climate commitments. As the company develops its sustainability framework, it is expected to adopt industry-standard climate terminology and practices to address its carbon footprint effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 302,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Bgp Pharma ULC's Industry?
How Carbon Intensive is Bgp Pharma ULC's Location?
Bgp Pharma ULC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bgp Pharma ULC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
